Collectively, current data position BCMA as the most advanced and clinically validated target for CAR-NK therapy in MM, bridging potent anti-myeloma activity with a favorable safety profile that may ultimately complement or extend the success of BCMA-directed CAR-T approaches. Here, TNFRSF17 is linked to Miyoshi myopathy.